340B Hospitals Could See Audits On Use Of Drug Price Savings Under Biden Administration Proposal
Legislation would be needed and will be complicated to develop. While the effectiveness of existing audits has been question by a federal government watchdog, the proposal in Biden’s budget document suggests the administration has some sympathy with drug sponsors’ position in the ongoing fight over the 340B drug discount program.
You may also be interested in...
340B Fight Escalates As Biden Administration Seeks Refunds From Manufacturers, Threatens Them With Fines
Lilly, AstraZeneca, Novartis, Sanofi, Novo Nordisk and United Therapeutics ordered by HRSA to resume discounts to 340B contract pharmacies and refund past 'overcharges.'
House Energy and Commerce Committee releases US Government Accountability Office analysis of 340B contract pharmacies.
Third US Senate committee hearing on 340B reforms focuses on the need for legislation requiring that providers report the drug discounts received and how they use the savings, but prospects for achieving change are unclear.